SCHEMBL3799998

SCHEMBL3799998

CCOc1ccccc1Nc1ncnc2sc(C)c(C)c12

nearest known ligand 0.61

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MAPK1 P28482 7/20 0.61
MAPT P10636 5/20 0.61
HTT P42858 4/20 0.61
HPGD P15428 1/20 0.61
SMN1; SMN2 Q16637 9/20 0.54
RAF1 P04049 3/20 0.54
GAA P10253 2/20 0.54
ALOX15 P16050 2/20 0.54
HSD17B10 Q99714 1/20 0.54
MKNK1 Q9BUB5 1/20 0.53
MKNK2 Q9HBH9 1/20 0.53
MEN1 O00255 3/20 0.52
KMT2A Q03164 3/20 0.52
LMNA P02545 3/20 0.52
NPSR1 Q6W5P4 2/20 0.51
ALDH1A1 P00352 2/20 0.51
MRGPRX1 Q96LB2 2/20 0.50
RAB9A P51151 2/20 0.48
PIP4K2C Q8TBX8 1/20 0.48
TSHR P16473 2/20 0.47

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3797945 0.90 MAPK1 (0.55) MAPK1MAPTHTTHPGDSMN1; SMN2
SCHEMBL3803478 0.89 MAPK1 (0.54) MAPK1MAPTHTTHPGDSMN1; SMN2
SCHEMBL3804302 0.88 MAPT (0.64) MAPK1MAPTHTTHPGDSMN1; SMN2
SCHEMBL3797070 0.87 MAPK1 (0.57) MAPK1MAPTHTTHPGDSMN1; SMN2
SCHEMBL3799181 0.86 MKNK2 (0.61) MKNK1MKNK2
SCHEMBL3802236 0.86 HTT (0.53) MAPK1MAPTHTTHPGDSMN1; SMN2
SCHEMBL3793908 0.85 MAPK1 (0.55) MAPK1MAPTHTTHPGDSMN1; SMN2
SCHEMBL3802978 0.85 MAPK1 (0.55) MAPK1MAPTHTTHPGDSMN1; SMN2
SCHEMBL3803487 0.84 MAPK1 (0.63) MAPK1MAPTHTTHPGDSMN1; SMN2
SCHEMBL3797936 0.84 MAPK1 (0.60) MAPK1MAPTHTTHPGDSMN1; SMN2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20100143341-A1 THIENOPYRIMIDINES FOR PHARMACEUTICAL COMPOSITIONS DEVELOGEN AKTIENGESELLSCHAFT (DE) 2010-06-10 US claimed
EP-1899353-A1 THIENOPYRIMIDINES FOR PHARMACEUTICAL COMPOSITIONS DeveloGen Aktiengesellschaft (DE) 2008-03-19 EP claimed
WO-2007059905-A9 THIENOPYRIMIDINES TREATING INFLAMMATORY DISEASES DEVELOGEN AG (DE) 2007-11-01 WO claimed
WO-2007059905-A2 THIENOPYRIMIDINES TREATING INFLAMMATORY DISEASES DEVELOGEN AKTIENGESELLSCHAFT (DE) 2007-05-31 WO claimed
WO-2006136402-A1 THIENOPYRIMIDINES FOR PHARMACEUTICAL COMPOSITIONS DEVELOGEN AKTIENGESELLSCHAFT (DE) 2006-12-28 WO claimed
US-20100143341-A1 THIENOPYRIMIDINES FOR PHARMACEUTICAL COMPOSITIONS DEVELOGEN AKTIENGESELLSCHAFT (DE) 2010-06-10 US disclosed
EP-1899353-A1 THIENOPYRIMIDINES FOR PHARMACEUTICAL COMPOSITIONS DeveloGen Aktiengesellschaft (DE) 2008-03-19 EP disclosed
WO-2007059905-A9 THIENOPYRIMIDINES TREATING INFLAMMATORY DISEASES DEVELOGEN AG (DE) 2007-11-01 WO disclosed
WO-2007059905-A2 THIENOPYRIMIDINES TREATING INFLAMMATORY DISEASES DEVELOGEN AKTIENGESELLSCHAFT (DE) 2007-05-31 WO disclosed
WO-2006136402-A1 THIENOPYRIMIDINES FOR PHARMACEUTICAL COMPOSITIONS DEVELOGEN AKTIENGESELLSCHAFT (DE) 2006-12-28 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100143341-A1 THIENOPYRIMIDINES FOR PHARMACEUTICAL COMPOSITIONS DTYMK, CMPK1, PDXK MAPK1 573/4885MAPT 2500/4885HTT 3454/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.